Skip to content
Head to head

argenx SE vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ARGX · VRTX

Updated 6 minutes ago

1-year performance, rebased to 100

ARGX -0.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals has the highest Quant Rating (62); Vertex Pharmaceuticals has done best over the past year (+22%).
ARGXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price925.70515.02
Change today-1.73%-1.08%
1-year return+0.8%+22.0%
Market cap$58.21B$130.58B
52-week range661.85 – 1,072.75412.27 – 568.67
Valuation
P/E (TTM)32.0633.14
P/E percentile, own 5-yr range69th99th
P/B6.926.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)19.5715.32
Net profit (TTM)$1.23B$3.88B
Revenue (TTM)$5.82B$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+52.7%+11.8%
Gross margin90.0%85.5%
Operating margin29.9%33.1%
Net margin32.2%30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date2014-06-292026-09-29
Ownership & sentiment
Institutional ownership72.4%96.8%
Insider activity (12mo)0 buy / 0 sell28 buy / 22 sell
Short interest (% of float)2.2%1.9%
Analyst consensus94% buy / 6% hold (16)95% buy / 5% hold (21)
Analyst price target$1,162 (+25%)$624 (+21%)
StockVane view
StockVane Quant RatingC (40)C (62)
Company
Employees3,5226,400
Founded20081989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.